Appareil pulmonaire IONESCO (IFCT-1601) A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer. Saint-Cloud MARIE ANGE MASSIANI
Appareil pulmonaire DS 73001-003 A PHASE 2, MULTICENTER, RANDOMIZED, OPENLABEL;STUDY OF DS-7300A, A B7-H3 ANTIBODY;DRUG CONJUGATE (ADC), IN SUBJECTS WITH;PRETREATED EXTENSIVE-STAGE SMALL CELL;LUNG CANCER (ES-SCLC). Paris PAULINE DU RUSQUEC
Appareil pulmonaire TAS6417-201 An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations. Paris NICOLAS GIRARD
Sein métastatique RH+ AIPAC AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel Saint-Cloud ETIENNE BRAIN
Sein métastatique RH+ BYLieve (CBYL719X402) A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment Saint-Cloud FLORENCE LEREBOURS
Recherches "plusieurs pathologies" AcSé Pembrolizumab Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types. Saint-Cloud CAROLE SOUSSAIN
Recherches "plusieurs pathologies" AcSé Vemurafenib Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Saint-Cloud ETIENNE BRAIN
Recherches "plusieurs pathologies" SUMMIT- PUMA-NER-0502 An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. Saint-Cloud FRANCOIS-CLEMENT BIDARD
Appareil Digestif IMMUNO-BIL (D48-1 PRODIGE 57) Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study Saint-Cloud
Sein métastatique RH+ DOLAF An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib Saint-Cloud